Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 12/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | APLNR | P35414 | 1/20 | 1.00 |
| ▸ | CX3CR1 | P49238 | 1/20 | 1.00 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoxetine SCHEMBL56333 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| R-Fluoxetine SCHEMBL3905325 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL8911991 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL3399076 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL7081402 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL570572 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| R-Fluoxetine SCHEMBL1200433 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL8467346 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL8353 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL33947 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 19909 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102486-A1 | METHOD FOR PRODUCING LOW ALCOHOL OR REDUCED ALCOHOL BEVERAGES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2026-05-21 | — | — | WO | claimed |
| WO-2025264511-A1 | LC RESONATOR FOR CASCODE AMPLIFIER STABILITY | PSEMI CORPORATION (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250392269-A1 | LC RESONATOR FOR CASCODE AMPLIFIER STABILITY | PSEMI CORP (US) | 2025-12-25 | — | — | US | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| US-20250319073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUNTINGTON’S DISEASE AND HTT PROTEINOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-10-16 | — | — | US | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250248940-A1 | Biopolymer Formulations for Drug Delivery | 11584022 CANADA INC. (CA) | 2025-08-07 | — | — | US | claimed |
| EP-4566590-A1 | TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF | Harbin Kanon Pharmaceutical Co., Ltd (CN) | 2025-06-11 | — | — | EP | claimed |
| EP-0219059-A2 | Apparatus for the hot tinning of circuit boards and process for soldering terminals of components to the conductive paths and soldering panels of a circuit board | Eidenberg, Kaspar (DE) | 1987-04-22 | — | — | EP | claimed |
| US-4647591-A | Method for improving memory | ELI LILLY AND COMPANY (US) | 1987-03-03 | — | — | US | claimed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | claimed |
| EP-0193354-A2 | Analgesic composition | ELI LILLY AND COMPANY (US) | 1986-09-03 | — | — | EP | claimed |
| EP-0193355-A2 | Analgesic composition | ELI LILLY AND COMPANY (US) | 1986-09-03 | — | — | EP | claimed |
| EP-0115271-B1 | STEELMAKING PROCESS USING CALCIUM CARBIDE AS FUEL | UNION CARBIDE CORPORATION (US) | 1986-08-27 | — | — | EP | claimed |
| US-4594358-A | Administering (nor)floxetine before dextropropoxyphene | ELI LILLY AND COMPANY (US) | 1986-06-10 | — | — | US | claimed |
| EP-0174512-A1 | Methode for connecting electrical leads with a winding on a bobbin | SIEMENS AKTIENGESELLSCHAFT (DE) | 1986-03-19 | — | — | EP | claimed |
| EP-0123469-A1 | Use of fluoxetine for the manufacture of an anti-anxiety agent | ELI LILLY AND COMPANY (US) | 1984-10-31 | — | — | EP | claimed |
| US-4329356-A | Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane | ELI LILLY AND COMPANY (US) | 1982-05-11 | — | — | US | claimed |